Home » News » CROs/Service Providers » Burrill & Company closes second Burrill Capital Fund IV

Burrill & Company closes second Burrill Capital Fund IV

Friday, August 3, 2012

Burrill & Company, a global life sciences financial services firm, announced a second close of its Burrill Capital Fund IV, bringing the aggregate capital commitments to $505 million.

The fund will invest globally in the life sciences, including early- to late-stage investments in therapeutics, diagnostics, medical devices, healthcare delivery, wellness, and digital health.

“We are pleased that our new fund generated strong interest among investors,” said G. Steven Burrill, CEO of Burrill & Company. “This is a time of great opportunities globally for investors in the life sciences, not just in traditional sectors, but emerging areas brought about by the convergence of healthcare and information technology.”

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!